E Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

E Fund Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,962	Closed	-$458K	–	329
2023 Q3	$458K	Sell	3,962 -539	-12%	-$57.9K	0.03%	137
2023 Q2	$463K	Buy	4,501 +991	+28%	+$105K	0.04%	123
2023 Q1	$383K	Sell	3,510 -836	-19%	-$92.4K	0.03%	180
2022 Q4	$495K	Sell	4,346 -2,861	-40%	-$238K	0.04%	130
2022 Q3	$446K	Buy	7,207 +2,081	+41%	+$145K	0.04%	149
2022 Q2	$409K	Buy	5,126 +2,463	+92%	+$233K	0.04%	185
2022 Q1	$280K	Buy	+2,663	New	+$260K	0.01%	225

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

E Fund Management's HZNP Position: Q4 2023 in Review

E Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 3,962 shares — an estimated $458K sold.

E Fund Management first reported a position in HZNP in Q1 2022 and held it in 7 quarters. The position peaked at $495K in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

E Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
E Fund Management sold 3,962 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $458K.
E Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 7 quarters.
E Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $495K in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on E Fund Management's 13F filing for Q4 2023, filed 7 Feb 2024.